Resources
metabolic
Weight management
GLP-1 and dual-agonist incretins have the strongest human RCT evidence on this index.
Outcomes this condition tracks
Why certain peptides surface — weighted by clinical relevance.
Weight / fat reduction
weight 1.00Strongest human RCT evidence on this index (GLP-1, dual-agonists).
Appetite & food-noise suppression
weight 0.90Primary mechanism on incretin lane.
Cardiometabolic health
weight 0.60Glycemic and lipid improvements co-travel with weight loss.
Evidence matrix
Outcome × ingredient signal — backed by indexed studies.
Each cell shows the clinical signal status and the count of indexed studies for that ingredient × outcome pair. Click any cell to open the ingredient brief.
| Outcome \ Ingredient | Semaglutide | Tirzepatide | Retatrutide | Cagrilintide | Tesamorelin |
|---|---|---|---|---|---|
| Weight / fat reduction | 4moderate | ·— | ·— | ·— | — |
| Appetite & food-noise suppression | ·— | ·— | ·— | ·— | — |
| Cardiometabolic health | ·— | ·— | ·— | ·— | ·— |
04Canonical, evidence-anchored
Matched protocol templates for this condition.
Matching templates…
Reported substances
What cohorts have used — and at what tier of evidence.
- SemaglutideGLP-1 receptor agonist0.25–2.4 mg/week, titratedHuman RCT→
- TirzepatideGIP / GLP-1 dual agonist2.5–15 mg/week, titratedHuman RCT→
- LiraglutideGLP-1 receptor agonist0.6–3.0 mg/dayHuman RCT→
- RetatrutideGIP / GLP-1 / glucagon triple agonist1–12 mg/week (trial)Human RCT→
- TesamorelinGHRH analogue (stabilised)2 mg/dayHuman RCT→
- Setmelanotideα-MSH analogue (MC4 selective)2–3 mg/dayHuman RCT→
- AOD-9604GH fragment (C-terminal)250–500 mcg/dayHuman RCT→
Suggestive, never prescriptive. Mydosage does not recommend a dose, a substance or a protocol. Decisions belong with you and a clinician.